{"doi":"10.1128/jcm.00593-24","title":"Comparison of the sensitivity and specificity of commercial anti-dengue virus IgG tests to identify persons eligible for dengue vaccination","abstract":"The Advisory Committee on Immunization Practices (ACIP) recommended that dengue pre-vaccination screening tests for Dengvaxia administration have at least 98% specificity and 75% sensitivity. This study evaluates the performance of commercial anti-DENV IgG tests to identify tests that could be used for pre-vaccination screening. First, for seven tests, we evaluated sensitivity and specificity in early convalescent dengue virus (DENV) infection, using 44 samples collected 7-30 days after symptom onset and confirmed by RT-PCR. Next, for the five best-performing tests and two additional tests (with and without an external test reader) that became available later, we evaluated performance to detect past dengue infection among a panel of 44 specimens collected in 2018-2019 from healthy 9- to 16-year-old children from Puerto Rico. Finally, a full-scale evaluation was done with the four best-performing tests using 400 specimens from the same population. We used virus focus reduction neutralization test and an in-house DENV IgG ELISA as reference standards. Of seven tests, five showed ≥75% sensitivity in detecting anti-DENV IgG in early convalescent specimens with low cross-reactivity to the Zika virus. For the detection of previous DENV infections, the tests with the highest performance were the Euroimmun NS1 IgG ELISA (sensitivity 84.5%, specificity 97.1%) and CTK Dengue IgG rapid test R0065C with the test reader (sensitivity 76.2% specificity 98.1%). There are IgG tests available that can be used to accurately classify individuals with previous DENV infection as eligible for dengue vaccination to support safe vaccine implementation. IMPORTANCE: The Advisory Committee on Immunization Practices (ACIP) has set forth recommendations that dengue pre-vaccination screening tests must exhibit at least 98% specificity and 75% sensitivity. Our research rigorously assesses the performance of various commercial tests against these benchmarks using well-characterized specimens from Puerto Rico. The findings from our study are particularly relevant given FDA approval and ACIP recommendation of Sanofi Pasteur's Dengvaxia vaccine, highlighting the need for accurate pre-vaccination screening tools.","journal":"Journal of Clinical Microbiology","year":2024,"id":435706,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9489,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1226232,"name":"Frances Vila","orcid":"0000-0003-0635-3010","position":1,"is_corresponding":false},{"id":335133,"name":"Laura E. Adams","orcid":"0000-0003-4698-7720","position":2,"is_corresponding":false},{"id":1243316,"name":"Jaime Cardona","orcid":"0009-0008-5973-5606","position":3,"is_corresponding":false},{"id":1243317,"name":"Jessica Carrión","orcid":"0000-0002-4379-6980","position":4,"is_corresponding":false},{"id":604471,"name":"Elaine W. Lamirande","orcid":"0000-0002-3597-7319","position":5,"is_corresponding":false},{"id":1243809,"name":"Luz N. Acosta","orcid":null,"position":6,"is_corresponding":false},{"id":1243810,"name":"Carlos M. De León-Rodríguez","orcid":null,"position":7,"is_corresponding":false},{"id":974870,"name":"Manuela Beltrán","orcid":"0000-0001-6185-2280","position":8,"is_corresponding":false},{"id":1243811,"name":"Demian Grau","orcid":null,"position":9,"is_corresponding":false},{"id":425794,"name":"Vanessa Rivera‐Amill","orcid":"0000-0003-4810-0871","position":10,"is_corresponding":false},{"id":549931,"name":"Ángel Balmaseda","orcid":"0009-0006-3812-5978","position":11,"is_corresponding":false},{"id":236674,"name":"Eva Harris","orcid":"0000-0002-7238-4037","position":12,"is_corresponding":false},{"id":383805,"name":"Zachary J. Madewell","orcid":"0000-0002-5667-9660","position":13,"is_corresponding":false},{"id":554331,"name":"Stephen H. Waterman","orcid":"0000-0003-4194-7914","position":14,"is_corresponding":false},{"id":374740,"name":"Gabriela Paz‐Bailey","orcid":"0000-0001-8478-4911","position":15,"is_corresponding":false},{"id":342842,"name":"Stephen S. Whitehead","orcid":"0000-0001-6707-482X","position":16,"is_corresponding":false},{"id":306899,"name":"Jorge L. Muñoz‐Jordán","orcid":"0000-0002-1596-8343","position":17,"is_corresponding":false},{"id":764226,"name":"Freddy A. Medina","orcid":"0000-0003-1320-593X","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:00:08.103086Z","pmid":"39194193","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}